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ABSTRACT
Objective: To identify which laboratory tests that
change over time are most valuable for the timely
diagnosis of macrophage activation syndrome (MAS)
complicating systemic juvenile idiopathic arthritis
(sJIA).
Methods: A multistep process, based on a
combination of expert consensus and analysis of real
patient data, was conducted. A panel of experts was
first asked to evaluate 115 profiles of patients with
MAS, which included the values of laboratory tests at
the pre-MAS visit and at MAS onset, and the change in
values between the two time points. The experts were
asked to choose the 5 laboratory tests in which change
was most important for the diagnosis of MAS and to
rank the 5 selected tests in order of importance. The
relevance of change in laboratory parameters was
further discussed and ranked by the same experts at a
consensus conference.
Results: Platelet count was the most frequently
selected test, followed by ferritin level, aspartate
aminotransferase (AST), white cell count, neutrophil
count, and fibrinogen and erythrocyte sedimentation
rate. Ferritin was most frequently assigned the
highest score. At the end of the process, platelet
count, ferritin level and AST were the laboratory tests
in which the experts found change over time to be
most important.
Conclusions: We identified the laboratory tests in
which change over time is most valuable for the
early diagnosis of MAS in sJIA. The dynamics of
laboratory values during the course of MAS should
be further scrutinised in a prospective study in order
to establish the optimal cut-off values for their
variation.
Key messages
What is already known on this subject?
▸ The change in laboratory values over time may
be more relevant for making an early diagnosis
of macrophage activation syndrome (MAS) in
the setting of systemic juvenile idiopathic arth-
ritis (sJIA) than the achievement of the absolute
threshold required by current diagnostic criteria.
What might this study add?
▸ The laboratory tests in which changes over time
are most valuable for the timely diagnosis of
MAS occurring in the context of sJIA were iden-
tified through a data-driven and consensus for-
mation approach.
How might this impact on clinical practice?
▸ Platelet count, serum ferritin and aspartate ami-
notransferase level are the laboratory biomar-
kers in which changes over time are most
helpful for the early detection of MAS in
patients with sJIA.
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INTRODUCTION
Macrophage activation syndrome (MAS) is a hyperin-
ﬂammatory complication of systemic juvenile idiopathic
arthritis (sJIA) caused by a highly stimulated but dysre-
gulated immune response that involves the sustained
activation and expansion of T lymphocytes and macro-
phages, and results in a cytokine storm syndrome.1–4 It is
a serious and potentially fatal condition, responsible for
much of the mortality observed in sJIA.5 6 MAS compli-
cates at least 10% of cases of sJIA, but a much higher
proportion of patients (30–40%) show signs of subclin-
ical MAS.7 8
Because MAS can pursue a rapidly fatal course if left
untreated, it requires prompt recognition to initiate
appropriate treatment and prevent deleterious out-
comes. However, early diagnosis is frequently difﬁcult,
given the lack of a single pathognomonic clinical or
laboratory parameter. Furthermore, histopathological
haemophagocytosis may not be detected in the initial
stages,9 10 or might not be discovered at all, and lacks
speciﬁcity for haemophagocytic syndromes.11 In add-
ition, the features of MAS may be hard to distinguish
from those conditions presenting with overlapping mani-
festations, such as ﬂares of sJIA or systemic infections.
The diagnostic challenges are compounded by the vari-
ability in the frequency and severity of the typical clinical
and laboratory features of the syndrome across
patients.12 13
The difﬁculties in making the diagnosis highlight the
need for accurate criteria to aid physicians in identifying
MAS in its earliest stages and in distinguishing it from
other conditions. Historically, two sets of guidelines have
been proposed for diagnosis of MAS in the setting of
sJIA: the diagnostic guidelines for haemophagocytic lym-
phohistiocytosis (HLH)-200414 and the preliminary diag-
nostic guidelines for MAS complicating sJIA.15 A set of
classiﬁcation criteria for sJIA-associated MAS was
recently developed through a multinational collaborative
effort.16
Although all these criteria are considered suitable for
detecting MAS in sJIA, it has been argued that the rela-
tive change in laboratory values over time may be more
relevant for making an early diagnosis than the decrease
below, or increase above, a certain threshold, as stipu-
lated by the criteria.1 16–19 Note that patients with active
sJIA often have elevated platelet counts as well as
increased levels of ferritin or ﬁbrinogen as part of the
underlying inﬂammatory process.20 21 Thus, the occur-
rence of a relative decline (in the case of platelet count
or ﬁbrinogen) or elevation (in the case of ferritin) in
these laboratory biomarkers, rather than the achieve-
ment of an absolute threshold required by the criteria,
may be sufﬁcient to herald the occurrence of MAS in
the setting of sJIA.12 18
One of the objectives of the international collaborative
project that led to the development of the novel classiﬁ-
cation criteria for MAS complicating sJIA,16 was to iden-
tify the laboratory tests in which change over time is
most valuable for the timely diagnosis of MAS occurring
in the context of sJIA. The results of this effort are
described in the present paper.
METHODS
Study design and data collection procedure
The multistep process strategy used in developing the
classiﬁcation criteria for MAS complicating sJIA has
been described in detail elsewhere.12 13 22 Brieﬂy, in the
ﬁrst phase of the project, international paediatric rheu-
matologists and paediatric haematologists were asked to
participate in a retrospective cohort study of patients
with sJIA-associated MAS and with two conditions poten-
tially confusable with MAS, represented by active sJIA
not complicated by MAS, and systemic infection. A total
of 1111 patients, 362 with sJIA-associated MAS, 404 with
active sJIA without MAS and 345 with systemic infection,
were reported by 95 paediatric subspecialists practising
in 33 countries on ﬁve continents. The features of these
patients have been described elsewhere.12 13 22 For the
purposes of the present study, only data of patients with
MAS were evaluated.
Collected information included laboratory features at
three time points: (1) at last visit before onset of MAS;
(2) at onset of MAS (deﬁned as the time when the
initial clinical and/or laboratory abnormalities suggest-
ing the occurrence of MAS were detected) and (3) at
full-blown MAS (deﬁned as the time at which MAS
reached its most severe stage). Because the present study
aimed to scrutinise the performance of the change in
laboratory tests in identifying MAS in its earlier stages,
only laboratory values recorded at last visit before onset
of MAS and at MAS onset were retained, and the
change in values was calculated between these two time
points. All laboratory parameters were tested using the
original values provided by each local laboratory.
Web-based consensus procedures among the experts
The second step of the process consisted of the evalu-
ation and ranking of the change over time in the most
typical laboratory parameters of MAS by a panel of
experts. The expert panel included 20 paediatric rheu-
matologists and 8 paediatric haematologists, selected
on the basis of their publication records and experi-
ence in the care of children with MAS and related
disorders.
The experts were asked to evaluate a total of 115 pro-
ﬁles of patients with sJIA with MAS. These proﬁles were
selected randomly among the 362 patients with sJIA with
MAS according to their caring physician. However, pref-
erence was given to the patients who had data for at
least ﬁve laboratory parameters at both aforementioned
time points available. A bias in the selection of patients
was unlikely, as the characteristics of selected and unse-
lected patients were comparable (data not shown). Each
patient proﬁle included the values of laboratory para-
meters at last visit before onset of MAS and at onset of
2 Ravelli A, et al. RMD Open 2016;2:e000161. doi:10.1136/rmdopen-2015-000161
RMD Open
group.bmj.com on April 6, 2017 - Published by http://rmdopen.bmj.com/Downloaded from 
MAS, the normal range of each parameter at the local
laboratory, and the absolute and percentage change of
values between the two time points. The following 11
laboratory tests were assessed: white cell count (WCC),
neutrophil count, haemoglobin, platelet count, erythro-
cyte sedimentation rate (ESR), aspartate aminotransfer-
ase (AST), lactic dehydrogenase, ﬁbrinogen,
triglycerides, ferritin and D-dimer.
Based on these data, all the experts were ﬁrst asked to
classify each patient proﬁle as MAS or non-MAS, that is,
to conﬁrm or not to conﬁrm the diagnosis of MAS
made by the caring physician. If the diagnosis of MAS
was conﬁrmed, the expert was ﬁrst asked to select the
ﬁve laboratory tests in which change over time was most
important in inﬂuencing his or her decision to categor-
ise the patient as having MAS. Then, the expert was
asked to rank the ﬁve selected laboratory tests in order
of importance by assigning 5 to the most important and
1 to the least important test.
The minimum level of agreement among the experts
about patient classiﬁcation as MAS or non-MAS was set
at 80%. If an 80% consensus was not attained, the
patient proﬁle was discussed in a further round. Two
rounds of voting were used, with comments and voting
from participants available, to augment the number of
consensus decisions. Proﬁles for which consensus was
not achieved at the ﬁnal round were declared non-
interpretable and discarded from further analyses.
Proﬁles for which consensus was reached among the
experts about the diagnosis of non-MAS were also
discarded.
All web-based consensus procedures were performed
electronically and conducted by the Pediatric
Rheumatology International Trials Organization
(PRINTO).
Ranking of laboratory tests at consensus conference
The International Consensus Conference on MAS
Classiﬁcation Criteria was held in Genoa, Italy, on 21–22
March 2014. The meeting was attended by all 28 experts
who participated in the web-consensus evaluations and
was facilitated by two moderators (NR and HB) with
expertise in nominal group technique (NGT). The ﬁrst
day of the conference was devoted to the development
of the classiﬁcation criteria for MAS complicating sJIA,16
whereas the diagnostic role of change in laboratory para-
meters was addressed on the second day.
Before the start of consensus evaluations, a plenary
session was held to illustrate the scope, methodology
and ﬂow of the overall project, the results of web-based
consensus procedures and the methodology of the NGT.
For the speciﬁc purpose of the present project, partici-
pants were shown the results of the web-consensus evalu-
ation of the relative diagnostic importance of the
change over time in the laboratory tests. These results
included the percentage of instances in which each test
was selected by the experts as well as the frequency of
individual scores (from 1 to 5) and the sum of scores
assigned to each test by the experts.
Participants were then randomised into two equally
sized nominal groups and, using NGT, were ﬁrst asked
to electronically select, independently of each other, the
ﬁve laboratory parameters in which change over time
was felt most important in the early diagnosis of MAS,
and then to rank the ﬁve selected parameters assigning
5 to the most important and 1 to the least important.
Voters were advised to base their choices on their
opinion about which of the laboratory tests and respect-
ive changes were easiest to use, and most credible
(face/content validity). The experts were connected by
laptops to a central computer and submitted all their
rankings electronically.
RESULTS
Results of the web-based consensus procedures among
the experts
After two rounds of web evaluations, the experts achieved
consensus on the classiﬁcation of 103 (89.6%) of the 115
patient proﬁles examined. Seventy patients (60.9%) were
classiﬁed as MAS, whereas 33 patients (28.7%) were
classiﬁed as non-MAS. For 12 patients (10.4%), consensus
was not reached. The 45 proﬁles classiﬁed as non-MAS or
for which consensus among the experts was not reached,
were discarded. Table 1 shows the comparison of demo-
graphic, clinical and histopathological features, triggers,
therapeutic interventions and outcome between patients
classiﬁed as MAS or non-MAS by the expert panel.
Compared with patients classiﬁed as non-MAS, patients
who had the diagnosis of MAS conﬁrmed by the experts
were younger at onset of MAS, and had a greater fre-
quency of fever and of most of the other typical clinical
features of the syndrome, had more frequently under-
gone a bone marrow aspiration or a lymphnode or liver
biopsy, were admitted more commonly to the intensive
care unit and had a greater frequency of death. The
gender ratio, duration of sJIA at MAS onset, triggers and
therapeutic interventions as well as the frequency of
bone marrow or biopsy haemophagocytosis, were com-
parable between the two groups. The comparison of the
change in laboratory parameters over time between
patients diagnosed as MAS or non-MAS by the experts is
presented in table 2. Overall, patients who had the diag-
nosis of MAS conﬁrmed by the experts had a greater
change in laboratory values than those classiﬁed as
non-MAS.
Table 3 shows, for each laboratory test evaluated by
the experts in the 70 patient proﬁles for which consen-
sus about the diagnosis of MAS was achieved, the
number and percentage of instances in which the test
was selected and the number of instances in which each
individual score was assigned to the test. The platelet
count was the most frequently selected test and achieved
the highest global score, followed by ferritin, AST, WCC,
neutrophils, ﬁbrinogen and ESR. However, ferritin was
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most frequently assigned the highest score of 5, whereas
platelet count was scored most commonly as 4; AST
most frequently received scores of 3, 2 and
1. Haemoglobin was the least frequently selected test,
whereas D-dimer had the lowest global score.
Final rank of laboratory tests at the consensus conference
After three voting sessions, the experts selected and
ranked 9 of the 11 laboratory parameters that were
examined (table 4). Ferritin was the parameter that
received the highest score, followed by platelet count,
AST, ﬁbrinogen, neutrophil count, WCC count, lactate
dehydrogenase (LDH), ESR and D-dimer. Haemoglobin
and triglycerides, among the ﬁve most important labora-
tory tests, were not selected by any expert.
DISCUSSION
Using a data-driven and consensus formation approach,
we identiﬁed the laboratory tests in which early change
is most valuable for the timely diagnosis of MAS in the
setting of sJIA. Platelet count, ferritin and AST were
Table 1 Comparison of demographic, clinical and histopathological features, triggers, treatments and outcome between
patients classified as MAS or non-MAS, by the expert panel*
N
Patients classified
as MAS (n=70) N
Patients classified
as non-MAS
(n=33)
p
Value
Demographic characteristics
Sex 70 33 0.81
Female 42 (60.0) 19 (57.6)
Male 28 (40.0) 14 (42.4)
Age at onset of MAS, median (IQR), years 69 10.5 (4.4–14.6) 32 7.6 (4.1–11.6) 0.01
Duration of systemic JIA at MAS onset,
median (IQR), years
69 0.9 (0.1–2.4) 31 1.5 (0.1–4.1) 0.31
Clinical manifestations at onset of MAS
Fever 69 68 (98.5) 33 28 (84.9) 0.01†
Hepatomegaly 67 50 (74.6) 33 16 (48.5) 0.01
Splenomegaly 65 37 (56.9) 33 16 (48.5) 0.43
Lymphadenopathy 65 36 (55.4) 32 8 (25.0) 0.005
Active arthritis 69 42 (60.9) 33 17 (51.5) 0.37
Central nervous system involvement 65 31 (47.7) 33 8 (24.2) 0.02
Haemorrhagic manifestations 67 26 (38.8) 33 4 (12.1) 0.006
Heart, lung or kidney failure 69 13 (18.8) 33 1 (3.0) 0.03
Triggers 0.49‡
Active disease 58 28 (48.3) 27 14 (51.8) –
Infection 58 23 (39.6) 27 7 (25.9) –
Treatment toxicity 58 1 (1.7) 27 3 (11.1) –
Other 58 3 (5.2) 27 2 (7.4) –
Unknown 58 3 (5.2) 27 2 (7.4) –
Histopathological features
Bone marrow aspiration and/or biopsy of l
ymphnode and/or liver
69 54 (78.3) 33 16 (48.5) 0.002
Haemophagocytosis on bone marrow
aspiration
and/or biopsy of lymphnode and/or liver
54 31 (57.4) 16 11 (68.7) 0.42
Therapeutic interventions
Any corticosteroids 69 68 (98.5) 33 33 (100.0) 1.0
Cyclosporine 69 47 (68.1) 33 24 (72.7) 0.64
Intravenous immunoglobulin 68 27 (39.7) 33 10 (30.3) 0.36
Biological medications† 68 17 (25.0) 33 9 (27.3) 0.81
Etoposide 67 10 (14.9) 33 4 (12.1) 1.0
Other immunosuppressants 66 5 (7.6) 32 3 (9.1) 0.71
Plasma exchange 67 6 (9.0) 33 2 (6.1) 1.0
Outcome
ICU admission 58 26 (44.8) 29 5 (17.2) 0.01
Death 69 7 (10.1) 33 0 (0.0) 0.01
*Except where indicated otherwise, data are the number (%).
†Administered biological medications included anakinra, tocilizumab, canakinumab, etanercept, abatacept, rituximab, alentuzumab.
‡The statistical comparison was made on the ensemble of triggering factors.
ICU, intensive care unit; JIA, juvenile idiopathic arthritis; MAS, macrophage activation syndrome.
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Table 2 Comparison of dynamics of laboratory tests over the course of MAS between patients classified as MAS or non-MAS by the expert panel*
Laboratory test
Patients classified as MAS (n=70) Patients classified as non-MAS (n=33)
p
Value†
p
Value‡n
Value at last
visit before
MAS onset
Value at
MAS
onset
Absolute
change
Percentage
change n
Value at last
visit before
MAS onset
Value at
MAS
onset
Absolute
change
Percentage
change
Hb, g/dL 70 11.2 9.9 −1.1 −10 33 11.5 10.8 −0.5 −5 0.070 0.030
WCC, ×109/L 70 15.0 7.4 −5.5 −50 33 10.8 12.0 1.6 11 <0.0001 <0.0001
N count, ×109/L 57 10.6 4.7 −5.5 −64 31 6.9 7.6 1.4 18 <0.0001 <0.0001
PLT, ×109/L 69 337 111 −209 −63 33 381 314 −62 −15 <0.0001 <0.0001
ESR, mm/h 62 59 26 −21 −39 26 33 61 8 59 <0.0001 <0.0001
AST, U/L 67 33 176 133 379 32 33 74 17 49 0.0002 0.0003
LDH, U/L 46 501 1735 1158 216 24 592 721 191 25 <0.0001 <0.0001
Triglycerides,
mg/dL
42 120 257 116 111 13 93 126 32 33 0.006 0.020
Fibrinogen,
mg/dL
44 456 201 −183 −47 20 510 454 −71 −22 0.010 0.010
Ferritin, ng/mL 60 875 10 516 7376 819 27 200 1183 548 282 <0.0001 0.03
D-dimer, ng/mL 23 1705 4620 2000 244 13 576 1237 300 100 0.09 0.19
*Values are the median (the IQRs can be provided on request to the authors). Absolute and percentage changes are the median values of the changes recorded in each individual patient.
†The p value refers to the comparison between absolute changes.
‡The p value refers to the comparison between percentage changes.
AST, aspartate aminotransferase; ESR, erythrocyte sedimentation rate; Hb, haemoglobin; LDH, lactate dehydrogenase; MAS, macrophage activation syndrome; N, neutrophils; PLT, platelets;
WCC, white cell count.
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agreed on by a panel of experts, as being most import-
ant after the web-based evaluation of a large sample of
sJIA with MAS patient proﬁles and face-to-face discus-
sion, and voting at the consensus conference.
In a previous analysis of the dynamics of laboratory
values over the course of MAS, Minoia et al12 found that
the three selected parameters, together with triglycer-
ides and LDH, followed the expected trend of change in
>90% of patients. Furthermore, platelet count, ferritin
and liver transaminases were among the ﬁve tests that
showed a percentage change of >50% between pre-MAS
visit and MAS onset. Of the ﬁve laboratory biomarkers
(which did not include ferritin and liver transaminases)
evaluated by Lehmberg et al,23 platelet count displayed
the largest decline between the measurements made
before the diagnosis of MAS and at the time of diagnosis
of MAS. Altogether, these ﬁndings are in keeping with
the experts’ choices.
Haemoglobin and triglycerides were the sole categor-
ies, among the ﬁve most important laboratory tests, that
were never selected by the experts at the consensus
conference. The less relevance given to haemoglobin
may be explained by the notion that children with active
sJIA often have marked anaemia as part of the under-
lying inﬂammatory process.24 25 Thus, the experts might
have perceived that when MAS develops there can fre-
quently be limited room for a further decrease in
haemoglobin. Note that, in the aforementioned Minoia
et al12 evaluation of the dynamics of laboratory values
over time, haemoglobin demonstrated a small median
percentage change (−8.8%).
The lack of choice of triglycerides is somewhat surpris-
ing, however. An increased triglyceride level is one of
the laboratory abnormalities included in the new classiﬁ-
cation criteria for MAS complicating sJIA.16 In addition,
in the Minoia et al12 analysis, triglycerides were among
the laboratory tests that followed the expected trend of
change in more than 90% of patients, and displayed a
percentage change of >50% between pre-MAS visit and
MAS onset. It can be hypothesised that the experts felt
that the variation in triglyceride level lags behind that of
other laboratory parameters or that there could be a
small dynamic change in level. Nevertheless, the time
course of triglyceridaemia during MAS should be
further explored in a prospective study.
Several episodes of MAS in patients with sJIA under
treatment with the cytokine blockers canakinumab and
tocilizumab have been recently observed in randomised
controlled clinical trials and in postmarketing experi-
ence.26–29 Because these agents inhibit the biological
effects of IL-1 and IL-6, respectively, which are among
the pro-inﬂammatory cytokines involved in the physio-
pathology of MAS,1 30 it is conceivable that their admin-
istration may modify the clinical and biological
presentation of MAS. Clinical symptoms of patients with
sJIA-associated MAS receiving tocilizumab were found to
be milder than those of patients not receiving this medi-
cation.31 However, more data from the real world of
Table 3 Number and percentage of instances in which each laboratory test was selected by the experts and number of
instances in which each individual score was assigned by the experts to each laboratory test during web consensus
procedures
Laboratory test N selected/n available (%)
Number of attributions
of individual scores* Sum of
scores5 4 3 2 1
Platelet count 1635/1821 (90) 679 609 238 78 31 6732
Ferritin 1363/1580 (86) 818 240 153 93 59 5754
Aspartate aminotransferase 1247/1767 (71) 30 118 322 477 300 2842
Fibrinogen 689/1164 (59) 27 143 169 184 166 1748
Neutrophil count 707/1502 (47) 74 221 168 132 112 2134
Lactate dehydrogenase 529/1212 (44) 2 43 104 171 209 1045
White cell count 769/1847 (42) 67 199 207 128 168 2176
D-dimer 254/606 (42) 1 16 53 78 106 490
Triglycerides 429/1110 (39) 0 6 50 130 243 677
Erythrocyte sedimentation rate 555/1632 (34) 13 78 150 149 165 1290
Haemoglobin 398/1847 (22) 4 42 101 95 156 837
*The score 5 was assigned to the most important laboratory test, whereas the score 1 was assigned to the least important.
Table 4 Scores assigned to laboratory tests at the
consensus conference
Laboratory test Score
Ferritin 109
Platelet count 105
Aspartate aminotransferase 58
Fibrinogen 32
Neutrophil count 20
Lactate dehydrogenase 15
White cell count 13
Erythrocyte sedimentation rate 5
D-dimer 3
Haemoglobin –
Triglycerides –
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clinical practice are needed to establish whether the
change in laboratory parameters over the course of MAS
occurring during treatment with IL-1 and IL-6 inhibitors
is more subtle than that in other instances of the
syndrome.
Our study should be interpreted in the light of some
potential caveats. All the study cases were deﬁned as MAS
based on clinician expert opinion. However, because all
patient proﬁles were reviewed by the experts and the
diagnosis of MAS or non-MAS was conﬁrmed only when
a high level of consensus was reached, the impact of this
potential limitation was likely minimised. Some import-
ant diagnostic parameters of MAS, such as sCD25 and
sCD163 levels, and natural killer cell activity, could not be
assessed owing to their unavailability in all patient
samples. However, in most paediatric rheumatology
centres, these biomarkers are neither routinely assessed
nor timely. Notably, other ongoing efforts, including the
study of patient cytokine proﬁles, may help in the per-
spective to distinguish MAS from active sJIA.32
We should also acknowledge that, because serial values
of laboratory tests were available for patients with MAS,
but not for control groups of patients with potentially
confusable conditions, we could not establish the thresh-
old level of change in each test that had the best sensitiv-
ity and speciﬁcity for the detection of MAS. Furthermore,
as we did not ask the investigators who entered their
patients’ information to include the date of the last visit
before the onset of MAS, we were unable to standardise
the time lag between the visits before onset of MAS and
at onset of MAS. These limitations precluded the incorp-
oration of the change in laboratory values over time in
the new classiﬁcation criteria for MAS complicating
sJIA.16
In summary, we identiﬁed the laboratory tests (platelet
count, and serum ferritin and AST levels) in which
changes over time are most valuable for the timely diag-
nosis of MAS occurring in the context of sJIA. The
dynamics of laboratory values during the course of MAS
should be further scrutinised prospectively at standar-
dised time points and with the inclusion of appropriate
groups of control patients in order to establish the
optimal cut-off values for their early variation.
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